Related Experiment Videos
Animal models of antisense oligonucleotides: lessons for use in humans
1Faculté de Médecine, Laboratoire d'Histopathologie Moléculaire Expérimentale, Vandoeurve Les Nancy, France. duprez@spieoa.u-nancy.fr
Abstract:
The ability of oligonucleotides to inhibit genetic expression in a sequence-specific manner has been well documented. Because of their potential for exquisite specificity, oligonucleotides have been proposed as therapeutic agents for a variety of human diseases, including cancers, microbial infections and autoimmune disorders. Approximately 16 clinical trials are currently in progress. However, relatively little is known about the in vivo behaviour of oligonucleotides. Extrapolations from in vitro studies to predict in vivo pharmacokinetics and effects in humans might be difficult and inappropriate. Animal models still remain an essential tool in the development of oligonucleotides as efficient drugs in humans.
Insights
Oligonucleotides show promise for treating diseases by inhibiting gene expression. Further research, particularly using animal models, is crucial to understand their in vivo behavior for effective human drug development.
Area of Science:
- Molecular Biology
- Pharmacology
- Biotechnology
Background:
- Oligonucleotides can inhibit genetic expression specifically.
- Their potential therapeutic applications include cancers, microbial infections, and autoimmune disorders.
- Numerous clinical trials are underway, highlighting their therapeutic promise.
Purpose of the Study:
- To investigate the in vivo behavior of oligonucleotides.
- To address the limitations of extrapolating in vitro data to human pharmacokinetics and effects.
- To emphasize the importance of animal models in oligonucleotide drug development.
Main Methods:
- Review of existing literature on oligonucleotide behavior.
- Analysis of in vitro study limitations for in vivo prediction.
- Highlighting the role of animal models in preclinical research.
Main Results:
- Limited understanding of in vivo oligonucleotide pharmacokinetics and biodistribution.
- In vitro data may not accurately predict in vivo efficacy or safety in humans.
- Animal models provide essential insights into in vivo oligonucleotide behavior.
Conclusions:
- Further in vivo studies are necessary to fully understand oligonucleotide behavior.
- Animal models are critical for the successful development of oligonucleotide therapeutics.
- Bridging the gap between in vitro findings and in vivo application is essential for clinical success.